BNN Bloomberg
🏢 Bell Media
Jul 27, 2026
· 1 min read
Quick Score
○ Unverifiable
View full audit trail →
Canadians may be eligible for a piece of this class-action involving a drug used to treat depression, schizophrenia - BNN Bloomberg
Original article ↗B.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
0.00 · CENTER
ML v2 (DistilBERT)
0.000 · CENTER
Ensemble
0.000 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.016
2,606 articles tracked
7-day bias trend
LcenterR
V.E.R.I.F.Y. has fact-checked this article.
Subscribe to see claim-by-claim verdicts and reasoning.
Subscribe to see claim-by-claim verdicts and reasoning.
Article Excerpt
The deadline is fast approaching for Canadians to claim their share of a multimillion-dollar class-action lawsuit over the drug Rexulti.
Canadians have until Aug. 27 to file a claim for their share of a $4.75 million settlement over the antipsychotic medication used to treat schizophrenia and depression.
Quebec Superior Court approved the settlement in November, one year after authorizing the national class action against Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada Inc.
The class action covers Canadians who were prescribed the drug since February 2017 and later developed compulsiv…
Read full article at BNN Bloomberg ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.